We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
-2.8%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$93M
AUM Growth
-$8.69M
Cap. Flow
-$1.29M
Cap. Flow %
-1.39%
Top 10 Hldgs %
87.33%
Holding
25
New
1
Increased
2
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$3.16M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$780K
3
OCRX
Ocera Therapeutics, Inc.
OCRX
+$130K

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$1.99M
2
ONC
BeOne Medicines Ltd
ONC
+$1.57M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$1.46M
4
RGNX icon
Regenxbio
RGNX
+$337K

Sector Composition

Rank Sector Weight
1 Healthcare 64.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$89.1M
$14.4M 15.43%
1,095,734
– –
CHRS icon
2
Coherus Oncology
CHRS
$216M
$8.6M 9.25%
305,505
– –
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.36B
$7.31M 7.86%
1,155,104
+150,000
+15% +$780K
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
$5.2M 5.59%
500,000
– –
RARX
5
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.53M 3.8%
+232,500
New +$3.16M
ADVM
6
DELISTED
Adverum Biotechnologies
ADVM
$3.2M 3.44%
110,274
– –
LPCN icon
7
Lipocine
LPCN
$18.4M
$3.13M 3.36%
49,995
– –
CLCD
8
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$2.48M 2.67%
68,190
– –
SIOX
9
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.29M 2.46%
23,014
– –
OCRX
10
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.92M 2.06%
912,050
+55,500
+6% +$130K
ASND icon
11
Ascendis Pharma A/S
ASND
$17.1B
$1.82M 1.96%
90,000
– –
PDSB icon
12
PDS Biotechnology
PDSB
$41.1M
$1.69M 1.82%
6,750
– –
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$1.45M 1.56%
135,420
– –
ARCT icon
14
Arcturus Therapeutics
ARCT
$172M
$1.38M 1.49%
94,130
– –
ORKA
15
Oruka Therapeutics
ORKA
$5.59B
$1.32M 1.42%
2,141
– –
AKTX
16
Akari Therapeutics
AKTX
$19.3M
$1.11M 1.2%
198
– –
CTMX icon
17
CytomX Therapeutics
CTMX
$788M
$706K 0.76%
64,200
– –
BOLD
18
DELISTED
Audentes Therapeutics, Inc
BOLD
$274K 0.29%
15,000
– –
SRRA
19
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$84K 0.09%
1,401
– –
SYRE icon
20
Spyre Therapeutics
SYRE
$8.7B
$26K 0.03%
240
– –
LRMR icon
21
Larimar Therapeutics
LRMR
$384M
– –
-50,176
Closed -$1.99M
RGNX icon
22
Regenxbio
RGNX
$511M
– –
-24,089
Closed -$337K
ONC
23
BeOne Medicines Ltd
ONC
$32.4B
– –
-51,000
Closed -$1.57M
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-180,000
Closed -$1.46M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.55% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q4 2016 Portfolio in Review

As of Q4 2016, VHCP Management held 25 positions worth $93M, down 8.5% from $102M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

VHCP Management's Q4 2016 filing shows 1 new, 2 increased and 4 closed positions. Its largest new stake was Ra Pharmaceuticals, Inc. Common Stock: 232,500 shares worth $3.53M. The largest sale was Larimar Therapeutics, an estimated $1.99M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier.

  • VHCP Management's largest Q4 2016 buy was Ra Pharmaceuticals, Inc. Common Stock: 232,500 shares worth $3.53M.
  • VHCP Management added most to BioCryst Pharmaceuticals in Q4 2016, an estimated $780K increase.
  • VHCP Management fully exited Larimar Therapeutics in Q4 2016, selling an estimated $1.99M.
  • VHCP Management's ten largest holdings make up 87% of its $93M portfolio in Q4 2016.
  • VHCP Management opened 1 new position and closed 4 in Q4 2016.
  • VHCP Management's portfolio value fell 8.5% quarter-over-quarter to $93M.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.